Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 7/20 | 0.61 |
| ▸ | RET | P07949 | 5/20 | 0.61 |
| ▸ | KIF5B | P33176 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 3/20 | 0.60 |
| ▸ | FLT1 | P17948 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18158243 | 0.92 | EGFR (0.72) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL30844364 | 0.89 | EGFR (0.73) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL29464032 | 0.89 | EGFR (0.73) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18153627 | 0.89 | EGFR (0.73) | EGFRRIPK2EPHB2KDRRET | |
| Hydrochloric Acid SCHEMBL29360029 | 0.88 | EGFR (0.72) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18158255 | 0.88 | EGFR (0.73) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18158267 | 0.88 | EGFR (0.76) | EGFRRIPK2EPHB2KDRRET | |
| Hydrochloric Acid SCHEMBL18153640 | 0.88 | EGFR (0.72) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18158239 | 0.87 | EGFR (0.73) | EGFRRIPK2EPHB2KDRRET | |
| SCHEMBL18158262 | 0.86 | EGFR (0.69) | EGFRRIPK2EPHB2KDRRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548897-B2 | KSR antagonists | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2016168704-A1 | KSR ANTAGONISTS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548897-B2 | KSR antagonists | KSR1, KSR2, KRAS | EGFR 182/4885RIPK2 1014/4885EPHB2 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.